Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Clarient to Offer BioMerieux's BRAF CDx

Premium

BioMérieux and Clarient, a GE Healthcare company, said this week that BioMérieux's molecular diagnostic test THxID-BRAF has been added to Clarient's service offerings.

The THxID-BRAF test is a real-time PCR-based companion diagnostic assay developed by BioMérieux, intended as an aid to oncologists in selecting melanoma patients who could benefit from treatments for their tumors that carry the BRAF V600E and V600K mutations. The assay received pre-market approval from the US Food and Drug Administration for commercialization in the US in May 2013.

Clarient will use THxID BRAF to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's Tafinlar (dabrafenib), as well as in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist (trametinib).

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.